UNCY - NASDAQ
Unicycive Therapeutics, Inc.
$7.23
+4.7%Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
At a Glance
Live SnapshotUNCY
Other Expenses
Last Annual Value
0.00
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Failed to load chart data
Unicycive Therapeutics, Inc. Competitors Analysis of other-expenses
| Company | other-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
No comparison data available We couldn't find other-expenses data for this stock's competitors. | |||||
Unicycive Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your UNCY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.